Future Oncology. 2013 April 605–609

Diagnostic use of epitope detection in monocytes blood test for early detection of colon cancer metastasis

Natalie Jansen1 & Johannes F Coy2

1 General practitioner, Happelstrasse 61, D-74074 Heilbronn, Germany

2 TAVARLIN AG, Landwehrstrasse 54, D-64293 Darmstadt, Germany

 

Abstract:

A follow-up strategy in cancer aftercare can result in early detection of metastasis and/or recurrence. Therefore, sensitive and reliable diagnostic tests that are easy to perform are needed. Here, the authors present the combined use of the epitope detection in monocytes (EDIM)–TKTL1 and EDIM–Apo10 blood test in aftercare monitoring of a patient with colon carcinoma. Whereas the established tumor markers CEA and CA19-9 did not indicate metastasis even at a timepoint where clinical signs and imaging techniques already demonstrated metastasis, the combined application of the EDIM–TKTL1 and the EDIM–Apo10 blood tests was positive 9 months before detection of metastasis. These findings – taken together with recently published evaluation data of the EDIM–TKTL1 blood test – suggest that the combined application of the EDIM–TKTL1 and the EDIM–Apo10 blood tests might indicate metastasis earlier than established tumor markers and could serve as sensitive and noninvasive methods that might be used for early detection of colon cancer metastasis.

Conclusion: This case report represents a first proof of concept that the EDIM–TKTL1 and EDIM–Apo10 blood tests might serve as sensitive and noninvasive methods and might be used for early detection of colon cancer metastasis. This needs to be explored in further evaluation studies.

PMID: 23560382

 

Supplement picture:

Alexandra Ohly-Jpg

This picture shows the basics of the EDIM-TKTL1 and EDIM-Apo10 blood test:

Copyright: TAVARLIN AG, 2013

 

Supplement information:

The epitope detection in monocytes (EDIM) has been established as a new technology for a noninvasive biomarker based detection and characterization of tumors (for example lung, breast and colon cancer) as well as early detection of recurrence and/or metastasis. (1,2) The biomarker Apo10 is highly specifically expressed in tumor cells irrespective of the tumor entity and accumulates due to blocked apoptosis. The detection of the Apo10 antigen in macrophages (EDIM-Apo10) demonstrates the presence of tumor cells which have been phagocytised (2,3,4,5). The transketolase-like-1 (TKTL1) gene contributes to a malignant phenotype through increased glucose metabolism and HIF1alpha accumulation and has been shown to favor tumor migration and metastasis (6). TKTL1 expression is associated with poor prognosis and therapy resistance in cancer patients (7,8).

Thus, the combined use of the biomarkers Apo10 and TKTL1 offers the possibility to detect abnormal cell proliferation and up-regulated glucose metabolism, indicating neoplasias and the degree of malignancy. The new EDIM-technology in combination with the biomarkers Apo10 and TKTL1 could be a useful tool to identify and monitor cancer patients and the use of new therapies in daily practice.

 

Reference: 

1.     Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.

2.     Jansen N und Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.

3.     Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. Journal of Clinical Oncology, ASCO Meeting Abstracts. 2013; 31:e22006.

4.     Rotmann A et al: Apo10 – a new biomarker for early detection of disorders of cell proliferation and solid tumours. FIGO 2012: Submission Number/Control ID: 1358244.

5.     Arnoldt J: Therapy monitoring and early detection of metastasis using tumor protein detection in macrophages. Anticancer Research ISSN 0250-7005: 2011 May:2012.

6.     Riganati et al:  The pentose phosphate pathway: An anti-oxidant defense and a cross-road in tumor cell fate, Free Radical Biology and Medicine, 2012.

7.     Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24.

8.     Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363.

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann